

# REAL-WORLD CLINICAL OUTCOMES ASSOCIATED WITH CANAGLIFLOZIN IN PATIENTS AGED 65 YEARS AND OLDER WITH TYPE 2 DIABETES MELLITUS IN SPAIN: THE OLD REAL-WECAN STUDY.

MANUEL GARGALLO-FERNANDEZ<sup>1</sup>, Alba Galdón Sanz-Pastor <sup>2</sup>, Teresa Antón-Bravo <sup>3</sup>, MIGUEL BRITO-SANFIEL<sup>4</sup>, Jaime Wong-Cruz <sup>5</sup>, and JUAN JOSE GORGOJO-MARTINEZ<sup>5</sup>

<sup>1</sup>Hospital Infanta Leonor

<sup>2</sup>Fundacion Jimenez Diaz-UTE

<sup>3</sup>Hospital Universitario de Móstoles

<sup>4</sup>Hospital Universitario Puerta del Hierro Majadahonda

<sup>5</sup>Hospital Universitario Fundacion Alcorcon

January 8, 2021

## Abstract

**Abstract Objectives** The observational REAL WE CAN study showed that canagliflozin 100 mg (CANA100) as add-on therapy, and canagliflozin 300 mg (CANA300), switching from prior SGLT-2i therapy, significantly improved several cardiometabolic parameters in patients with T2DM. The aim of this sub-analysis was to assess the effectiveness and safety of canagliflozin in patients aged >65 years. The primary outcome of the study was the mean change in HbA1c over the follow-up time. **Materials and Methods** 583 patients met the inclusion criteria (39.5% > 65 years), 279 in the CANA100 cohort (36.9 % > 65 years, mean HbA1c 8.05%) and 304 in the CANA300 cohort (41.8 % > 65 years, mean HbA1c 7.51%). **Results** In the CANA100 cohort, older patients showed significant reductions in HbA1c (-0.78%) and weight (-4.5 kg). Patients aged >65 years switching to CANA300 experienced a significant decrease in HbA1c (-0.27%) and weight (-2.1 kg). There were no significant differences in HbA1c and weight reductions when the cohorts of patients <65 and >65 years were compared in a multiple linear regression model. The safety profile of canagliflozin was similar in both age groups. **Conclusion** These findings support canagliflozin as an effective therapeutic option for older adults with T2DM

Dr Manuel A Gargallo-Fernandez

Endocrinology Department

Hospital Infanta Leonor

Fundacion Jimenes Diaz

Madrid

Spain

Dr Charles Young BSc

Editor-in-Chief IJCP

January 6, 2021

Dear Dr. Young:

I am pleased to submit an original research article entitled “REAL-WORLD CLINICAL OUTCOMES ASSOCIATED WITH CANAGLIFLOZIN IN PATIENTS AGED 65 YEARS AND OLDER WITH TYPE 2 DIABETES MELLITUS IN SPAIN: THE OLD REAL-WE CAN STUDY” for consideration for publication in the *International Journal of Clinical Practice*.

We have previously reported the effectiveness of canagliflozin 100 and the switch to canagliflozin 300 from a prior SGLT-2i in patients with T2DM in a real world setting (*Gorgojo-Martínez JJ, Gargallo-Fernández MA, Galdón Sanz-Pastor A, Antón-Bravo T, Brito-Sanfiel M, Wong-Cruz J. Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study. J Clin Med. 2020; 9: 2275*), now this manuscript show the subanalysis results of our prior study to assess the effectiveness and safety of canagliflozin in patients aged > 65 years.


Given the scarce data about effectiveness of canagliflozin in older patients, and the lack of data about switching to canagliflozin 300 from any SGLT-2i in the increasing number of T2DM patients older than 65 years, we believe that this manuscript is appropriate for publication by

*International Journal of Clinical Practice*.

This manuscript has not been published and is not under consideration for publication elsewhere.

Thank you for your consideration!

Sincerely,

A handwritten signature in black ink, reading "M. Gargallo". The signature is written in a cursive style with a long horizontal line extending from the end of the name.

Manuel A Gargallo

#### Hosted file

Dr Gargallo manuscript.pdf available at <https://authorea.com/users/388226/articles/503059-real-world-clinical-outcomes-associated-with-canagliflozin-in-patients-aged-65-years-and-older-with-type-2-diabetes-mellitus-in-spain-the-old-real-wecan-study>

#### Hosted file

Dr Gargallo Tables.pdf available at <https://authorea.com/users/388226/articles/503059-real-world-clinical-outcomes-associated-with-canagliflozin-in-patients-aged-65-years-and-older-with-type-2-diabetes-mellitus-in-spain-the-old-real-wecan-study>